and lymphatic system disorders
: Agranulocytosis, thrombocytopenia,
pancytopenia, anemia, leukopenia, neutropenia; individual cases of hemolytic
anemia in patients with congenital deficiency of glucose-6-phosphate
dehydrogenase (G6PD) have been reported with other ACE inhibitors.
Metabolism and nutrition disorders:
Hyperkalemia, hypoglycemia, thirst.
Depression, sleep disorders, insomnia, sleepiness.
Dizziness, postural dizziness, somnolence, paresthesia,
disorder of balance, confusion, headache, taste disturbance, lightheadedness,
cerebral hemorrhage, cerebrovascular disorders.
and labyrinth disorders:
Tachycardia, palpitations, arrhythmia, angina pectoris, myocardial
Severe hypotension after initiation of therapy or increase of dose;
dizziness, feeling of weakness, impaired vision, and disturbance of
consciousness (syncope) can also occur in association with hypotension;
transient ischemic attack, facial flushing.
thoracic and mediastinal disorders:
Cough, pharynx discomfort, hoarseness,
dyspnea, sinusitis, rhinitis, glossitis, bronchitis, bronchospasm, upper respiratory
tract infection, angioedema involving the upper airways, allergic
alveolitis/eosinophilic pneumonia (very rare).
Diarrhea, nausea, queasy, vomiting, gastritis, abdominal pain,
constipation, dry mouth, stomach discomfort, anorexia, ileus, pancreatitis,
epigastric pain, dyspepsia, intestinal angioedema.
Cholestatic icterus, hepatitis, jaundice.
and subcutaneous tissue disorders:
Photosensitivity, allergic and
hypersensitivity reactions such as rash, pruritus, exanthema, and urticaria,
erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis,
exfoliative dermatitis, pemphigus-like symptoms, psoriasis-like efflorescences,
alopecia, cutaneous symptoms accompanied by fever, myalgia, arthralgia,
eosinophilia and/or increased antinuclear antibody (ANA) titers; angioneurotic
edema involving the face and oropharyngeal tissues.
and urinary disorders:
Renal impairment, acute renal failure, proteinuria,
aggravation of renal function disorder.
disorders and administration site conditions:
Feeling of weakness, numbness,
fatigue, malaise, weariness, edema, chest discomfort, chest pain, pain in limbs.
system and breast disorders:
Increases in blood urea nitrogen, plasma creatinine, serum potassium, liver
enzymes, aspartate aminotrasnferase (AST), alanine aminotransferase, alkaline
phosphatase (ALP), lactate dehydrogenase (LDH), γ-glutamyl transpeptidase (γ-GTP), serum bilirubin,
creatine phosphokinase (CPK); decreases in erythrocyte, thrombocyte, leukocyte,
hemoglobin, hematocrit, platelets, white blood cell count.